Boxer Capital’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Boxer Capital’s Portfolio BLPH Stock Details BLPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-98,809	Closed	-$1.24M	–	79
2020 Q2	$1.24M	Hold	98,809	–	–	0.05%	63
2020 Q1	$1.08M	Buy	+98,809	New	+$662K	0.07%	61
2018 Q4	–	Sell	-98,810	Closed	-$1.6M	–	30
2018 Q3	$1.6M	Sell	98,810 -25,000	-20%	-$594K	0.18%	22
2018 Q2	$4.49M	Hold	123,810	–	–	0.51%	23
2018 Q1	$3.86M	Hold	123,810	–	–	0.41%	27
2017 Q4	$4.79M	Hold	123,810	–	–	0.88%	21
2017 Q3	$2.64M	Hold	123,810	–	–	0.6%	22
2017 Q2	$2.49M	Hold	123,810	–	–	0.59%	22
2017 Q1	$2.77M	Hold	123,810	–	–	0.6%	21
2016 Q4	$966K	Buy	+123,810	New	+$1.72M	0.37%	24

Other funds holding BLPH

PCM

Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return

NMVA

New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boxer Capital's BLPH Position: Q3 2020 in Review

Boxer Capital sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q3 2020, closing a stake of 98,809 shares — an estimated $1.24M sold.

Boxer Capital first reported a position in BLPH in Q4 2016 and held it in 10 quarters. The position peaked at $4.79M in Q4 2017. 41 funds tracked by Wall St. Rank hold BLPH as of Q3 2020.

Boxer Capital reported no remaining Bellerophon Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
Boxer Capital sold 98,809 Bellerophon Therapeutics, Inc. shares in Q3 2020, an estimated $1.24M.
Boxer Capital first reported a position in Bellerophon Therapeutics, Inc. in Q4 2016 and held it in 10 quarters.
Boxer Capital's Bellerophon Therapeutics, Inc. position peaked at $4.79M in Q4 2017.
41 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q3 2020.

Based on Boxer Capital's 13F filing for Q3 2020, filed 16 Nov 2020.